• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

证据审查组对 NICE STA 流程中制造商提交材料进行关键评估的方法:一项映射研究和主题分析。

Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.

机构信息

School of Health and Related Research (ScHARR) Technology Assessment Group, University of Sheffield, Sheffield, UK.

出版信息

Health Technol Assess. 2011 May;15(22):1-82, iii-iv. doi: 10.3310/hta15220.

DOI:10.3310/hta15220
PMID:21561569
Abstract

BACKGROUND

The National Institute for Health and Clinical Excellence (NICE) single technology appraisal (STA) process was set up as a rapid way to appraise new technologies for use within the NHS in England and Wales and has been in place since 2005.

OBJECTIVES

This study had five primary objectives: (1) to provide a map of the STA process to date; (2) to identify current approaches to the critical appraisal of manufacturers' submissions (MSs) by Evidence Review Groups (ERGs); (3) to identify recurring themes in clarification letters sent to manufacturers; (4) to provide recommendations for possible alternative approaches to be used in the critical appraisal process; and (5) to revise the current ERG report template.

DATA SOURCES

Data for the mapping of the STA process were obtained from the NICE website (www.nice.org.uk). Data for the analyses of the ERG reports and clarification letters were taken from the reports and letters themselves.

REVIEW METHODS

For the mapping, a spreadsheet was developed to collect data on 22 predefined variables related to timings and outcomes. Simple descriptive statistics were used to analyse the data. For the thematic analysis, a documentary analysis of 30 ERG reports was undertaken. Data on key elements of the MSs, the processes undertaken by ERGs and the strengths and weaknesses of MSs were extracted. A framework of a priori themes was developed. Data were extracted, coded and analysed according to a framework approach. Twenty-one clarification letters were examined and data were extracted using a set of codes to cover report quality, systematic review methods and clinical/economic issues. The current ERG report template was modified and sent to the current ERG teams for comment. All comments were considered and formed the basis for further revisions to the template.

RESULTS

Ninety-five STAs were included in the mapping exercise. Many STAs were subject to delay or cancellation for a variety of reasons. The ERG reports highlighted the strengths and weaknesses of MSs to the STA process. Thematic analysis of these data offered a means of clarifying and describing these aspects of the submissions. This analysis generated five themes: process, reporting, satisfaction of objectives, reliability and validity of findings, and content. Points from clarification letters were analysed and presented in four main categories: report quality, systematic review methods, clinical data analysis and economic data analysis.

LIMITATIONS

Nearly all data were obtained from the NICE website; therefore, any errors in the data on the website will be reflected in the mapping analysis presented in this report. Missing data for the mapping exercise limit the generalisability of the findings. Analyses were limited to what was reported in the ERG reports and the clarification letters.

CONCLUSIONS

Guidance suggested for manufacturers will help to ensure that more appropriate submissions are received in the future while recommendations provided for ERG teams will help to guide teams to ensure that reporting methods are transparent.

FUNDING

The National Institute for Health Research Health Technology Assessment programme.

摘要

背景

国家卫生与临床优化研究所(NICE)的单一技术评估(STA)程序是作为一种快速评估新英格兰和威尔士国民保健制度(NHS)中使用的新技术的方法而设立的,自 2005 年以来一直在使用。

目的

本研究有五个主要目标:(1)提供 STA 流程的概述;(2)确定当前证据审查小组(ERG)对制造商提交材料(MS)进行关键评估的方法;(3)确定向制造商发送澄清函中反复出现的主题;(4)提供对可能用于关键评估过程的替代方法的建议;(5)修改当前 ERG 报告模板。

数据来源

STA 流程的映射数据来自 NICE 网站(www.nice.org.uk)。ERG 报告和澄清函的分析数据取自报告和函件本身。

审查方法

为了进行概述,开发了一个电子表格来收集 22 个与时间安排和结果相关的预定义变量的数据。使用简单的描述性统计来分析数据。对于主题分析,对 30 份 ERG 报告进行了文献分析。提取了 MS 中的关键要素、ERG 所进行的流程以及 MS 的优缺点。制定了一个预先设定主题的框架。根据框架方法提取、编码和分析数据。对 21 封澄清函进行了审查,并使用一组代码提取报告质量、系统评价方法和临床/经济问题的数据。修改了当前的 ERG 报告模板,并将其发送给当前的 ERG 团队征求意见。考虑了所有意见,并以此为基础进一步修改了模板。

结果

95 项 STA 纳入了概述工作。由于各种原因,许多 STA 都被推迟或取消。ERG 报告向 STA 流程强调了 MS 的优缺点。对这些数据的主题分析提供了一种澄清和描述提交内容的方法。这一分析产生了五个主题:流程、报告、目标满意度、发现的可靠性和有效性以及内容。澄清函中的要点根据四个主要类别进行了分析和呈现:报告质量、系统评价方法、临床数据分析和经济数据分析。

局限性

几乎所有数据均来自 NICE 网站;因此,网站上数据的任何错误都将反映在本报告中呈现的概述分析中。概述工作中缺失的数据限制了研究结果的普遍性。分析仅限于 ERG 报告和澄清函中报告的内容。

结论

为制造商提供的指导建议将有助于确保未来收到更合适的提交材料,同时为 ERG 团队提供的建议将有助于指导团队确保报告方法透明。

资助

英国国家卫生研究院卫生技术评估计划。

相似文献

1
Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis.证据审查组对 NICE STA 流程中制造商提交材料进行关键评估的方法:一项映射研究和主题分析。
Health Technol Assess. 2011 May;15(22):1-82, iii-iv. doi: 10.3310/hta15220.
2
A thematic analysis of the strengths and weaknesses of manufacturers' submissions to the NICE Single Technology Assessment (STA) process.对制造商向 NICE 单一技术评估(STA)流程提交内容的优缺点进行主题分析。
Health Policy. 2011 Oct;102(2-3):136-44. doi: 10.1016/j.healthpol.2011.06.002. Epub 2011 Jul 16.
3
The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis.在英国国家卫生与临床优化研究所(NICE)单一技术评估过程中使用探索性分析:评估与定性分析。
Health Technol Assess. 2016 Apr;20(26):1-48. doi: 10.3310/hta20260.
4
Procedures and methods of benefit assessments for medicines in Germany.德国药品效益评估的程序和方法。
Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.
5
[Procedures and methods of benefit assessments for medicines in Germany].[德国药品效益评估的程序和方法]
Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25.
6
A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process.对制造商提交给英国国家卫生与临床优化研究所单一技术评估流程的材料进行的定性研究。
BMJ Open. 2012 Feb 8;2(1):e000562. doi: 10.1136/bmjopen-2011-000562. Print 2012.
7
The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process.英国国家卫生与临床优化研究所单一技术评估过程中证据审查小组探索性分析的类型及影响
Value Health. 2017 Jun;20(6):785-791. doi: 10.1016/j.jval.2016.08.729. Epub 2016 Oct 21.
8
Assessing searches in NICE single technology appraisals: practice and checklist.评估 NICE 单一技术评估中的检索:实践和清单。
Int J Technol Assess Health Care. 2013 Jul;29(3):315-22. doi: 10.1017/S0266462313000330. Epub 2013 Jun 17.
9
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.磷酸氟达拉滨用于慢性淋巴细胞白血病的一线治疗。
Health Technol Assess. 2009 Jun;13 Suppl 1:35-40. doi: 10.3310/hta13suppl1/06.
10
Infliximab for the treatment of adults with psoriasis.英夫利昔单抗用于治疗成人银屑病。
Health Technol Assess. 2009 Jun;13 Suppl 1:55-60. doi: 10.3310/hta13suppl1/09.

引用本文的文献

1
A Review of the Utilization of Relative Dose Intensity and Dose Delay Factor in Health Technology Appraisals of Oncology Drugs in Solid Tumors.实体瘤中肿瘤药物卫生技术评估中相对剂量强度和剂量延迟因子的应用综述
Adv Ther. 2025 Sep 4. doi: 10.1007/s12325-025-03358-6.
2
Conducting Value for Money Analyses for Non-randomised Interventional Studies Including Service Evaluations: An Educational Review with Recommendations.针对非随机干预性研究(包括服务评估)进行性价比分析:教育评论及建议。
Pharmacoeconomics. 2020 Jul;38(7):665-681. doi: 10.1007/s40273-020-00907-5.
3
Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process.
英国国家卫生与临床优化研究所单一技术评估过程中证据审查小组的探索性分析频率相关问题。
Pharmacoecon Open. 2017 Jun;1(2):99-108. doi: 10.1007/s41669-016-0001-4.
4
Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries.利用健康技术评估来评估新药的价值:在八个欧洲国家进行的系统评价和专家咨询的结果。
Eur J Health Econ. 2018 Jan;19(1):123-152. doi: 10.1007/s10198-017-0871-0. Epub 2017 Mar 16.
5
Modeling Treatment Sequences in Pharmacoeconomic Models.药物经济学模型中的治疗序列建模
Pharmacoeconomics. 2017 Jan;35(1):15-24. doi: 10.1007/s40273-016-0455-3.
6
Selecting the Acceptance Criteria of Medicines in the Reimbursement List of Public Health Insurance of Iran, Using the "Borda" Method: a Pilot Study.运用“博尔达”方法选择伊朗公共医疗保险报销目录中的药品纳入标准:一项试点研究
Iran J Pharm Res. 2015 Fall;14(4):1305-16.
7
A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process.对制造商提交给英国国家卫生与临床优化研究所单一技术评估流程的材料进行的定性研究。
BMJ Open. 2012 Feb 8;2(1):e000562. doi: 10.1136/bmjopen-2011-000562. Print 2012.